NASDAQ:ALGS Aligos Therapeutics (ALGS) Stock Price, News & Analysis $13.75 -0.73 (-5.04%) (As of 08/21/2024 ET) Add Compare Share Share Today's Range$13.50▼$14.2550-Day Range$8.75▼$14.4852-Week Range$8.70▼$30.00Volume40,742 shsAverage Volume15,595 shsMarket Capitalization$1.07 billionP/E RatioN/ADividend YieldN/APrice Target$75.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Aligos Therapeutics alerts: Email Address Aligos Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside445.5% Upside$75.00 Price TargetShort InterestHealthy0.36% of Shares Sold ShortDividend StrengthN/ASustainability-0.80Upright™ Environmental ScoreNews Sentiment0.19Based on 14 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.73) to ($0.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.25 out of 5 starsMedical Sector140th out of 924 stocksBiological Products, Except Diagnostic Industry17th out of 145 stocks 3.5 Analyst's Opinion Consensus RatingAligos Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAligos Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Aligos Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.36% of the outstanding shares of Aligos Therapeutics have been sold short.Short Interest Ratio / Days to CoverAligos Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aligos Therapeutics has recently increased by 13.12%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAligos Therapeutics does not currently pay a dividend.Dividend GrowthAligos Therapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAligos Therapeutics has received a 76.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services of the circulatory system", "Clinical research services for metabolic diseases", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Aligos Therapeutics is -0.80. Previous Next 2.3 News and Social Media Coverage News SentimentAligos Therapeutics has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Aligos Therapeutics this week, compared to 1 article on an average week.Search Interest3 people have searched for ALGS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Aligos Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aligos Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders16.50% of the stock of Aligos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions60.43% of the stock of Aligos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aligos Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aligos Therapeutics are expected to grow in the coming year, from ($0.73) to ($0.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aligos Therapeutics is -10.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aligos Therapeutics is -10.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAligos Therapeutics has a P/B Ratio of 11.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Aligos Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Darwin2024's Must-Watch Stocks!Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. [Unlock Your Report Now] About Aligos Therapeutics Stock (NASDAQ:ALGS)Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Read More ALGS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALGS Stock News HeadlinesAugust 21 at 7:16 AM | americanbankingnews.comAligos Therapeutics (NASDAQ:ALGS) Shares Gap Up to $13.13August 21 at 3:05 AM | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Purple Biotech (PPBT) and Aligos Therapeutics (ALGS)August 22, 2024 | Investors Alley (Ad)Grab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck worries melt away...August 20 at 8:27 AM | msn.comHC Wainwright & Co. Initiates Coverage of Aligos Therapeutics (ALGS) with Buy RecommendationAugust 19 at 7:24 AM | americanbankingnews.comAligos Therapeutics (NASDAQ:ALGS) Coverage Initiated by Analysts at HC WainwrightAugust 18, 2024 | ca.finance.yahoo.com5WK.SG,0P0001LPS2,0 (5WK.SG)August 18, 2024 | ca.finance.yahoo.comAligos Therapeutics Inc (5WK.DU)August 17, 2024 | americanbankingnews.comAligos Therapeutics (NASDAQ:ALGS) Shares Scheduled to Reverse Split on Monday, August 19thAugust 22, 2024 | Investors Alley (Ad)Grab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck worries melt away...August 17, 2024 | americanbankingnews.comAligos Therapeutics Stock Scheduled to Reverse Split on Monday, August 19th (NASDAQ:ALGS)August 15, 2024 | ca.finance.yahoo.comOXO.SG,0P0000BSRG,0 (OXO.SG)August 15, 2024 | globenewswire.comAligos Therapeutics Announces Reverse Stock SplitAugust 8, 2024 | globenewswire.comAligos Therapeutics Strengthens Board with Two New Independent DirectorsAugust 6, 2024 | tmcnet.comAligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial ResultsJuly 29, 2024 | finance.yahoo.comCompanies Like Aligos Therapeutics (NASDAQ:ALGS) Could Be Quite RiskyJuly 22, 2024 | globenewswire.comAligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.July 10, 2024 | globenewswire.comAligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHBJune 5, 2024 | globenewswire.comAligos Therapeutics Presents Positive Data at the EASL Congress 2024See More Headlines Receive ALGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today8/21/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALGS CUSIPN/A CIK1799448 Webwww.aligos.com Phone800-466-6059FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$75.00 High Stock Price Target$75.00 Low Stock Price Target$75.00 Potential Upside/Downside+445.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,680,000.00 Net Margins-783.72% Pretax Margin-777.58% Return on Equity-144.16% Return on Assets-84.50% Debt Debt-to-Equity RatioN/A Current Ratio6.25 Quick Ratio6.25 Sales & Book Value Annual Sales$7.97 million Price / Sales134.81 Cash FlowN/A Price / Cash FlowN/A Book Value$1.23 per share Price / Book11.18Miscellaneous Outstanding Shares78,110,000Free Float65,222,000Market Cap$1.07 billion OptionableOptionable Beta2.18 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Lawrence M. Blatt MBA (Age 62)Ph.D., CEO, President & Chairman of the Board Comp: $1.03MDr. Julian A. Symons DPHIL (Age 62)Executive VP & Chief Scientific Officer Comp: $735.51kDr. Matthew W. McClure M.D. (Age 52)Executive VP & Chief Medical Officer Comp: $740.39kKristina EngesethVP and Head of People & CultureDr. Sushmita M. Chanda DABT (Age 57)Ph.D., Executive Vice President & Chief Development Officer Dr. David B. Smith Ph.D.Executive VP & Head of Chemical OperationsDr. Tse-I Lin Ph.D.VP of Early Compound Development & Belgian Site HeadMore ExecutivesKey CompetitorsDynavax TechnologiesNASDAQ:DVAXArbutus BiopharmaNASDAQ:ABUSAssembly BiosciencesNASDAQ:ASMBDicerna PharmaceuticalsNASDAQ:DRNAUltragenyx PharmaceuticalNASDAQ:RAREView All CompetitorsInsiders & InstitutionsArmistice Capital LLCBought 363,000 shares on 8/15/2024Ownership: 9.290%Renaissance Technologies LLCSold 39,421 shares on 8/9/2024Ownership: 0.984%Versant Venture Management LLCSold 862,444 shares on 8/8/2024Ownership: 1.867%Acadian Asset Management LLCBought 171,490 shares on 8/6/2024Ownership: 1.062%Opaleye Management Inc.Bought 333,000 shares on 5/29/2024Ownership: 2.087%View All Insider TransactionsView All Institutional Transactions ALGS Stock Analysis - Frequently Asked Questions How have ALGS shares performed this year? Aligos Therapeutics' stock was trading at $16.60 at the beginning of the year. Since then, ALGS shares have decreased by 17.2% and is now trading at $13.75. View the best growth stocks for 2024 here. How were Aligos Therapeutics' earnings last quarter? Aligos Therapeutics, Inc. (NASDAQ:ALGS) issued its quarterly earnings results on Tuesday, August, 6th. The company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.00) by $4.75. The business earned $1.06 million during the quarter. Aligos Therapeutics had a negative net margin of 783.72% and a negative trailing twelve-month return on equity of 144.16%. When did Aligos Therapeutics' stock split? Aligos Therapeutics's stock reverse split before market open on Monday, August 19th 2024. The 1-25 reverse split was announced on Thursday, August 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Aligos Therapeutics IPO? Aligos Therapeutics (ALGS) raised $150 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P.Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO and Cantor was co-manager. Who are Aligos Therapeutics' major shareholders? Aligos Therapeutics' top institutional shareholders include Armistice Capital LLC (9.29%), Versant Venture Management LLC (1.87%), Acadian Asset Management LLC (1.06%) and Renaissance Technologies LLC (0.98%). View institutional ownership trends. How do I buy shares of Aligos Therapeutics? Shares of ALGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALGS) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThe #1 A.I. Crypto You Don’t Own (YET!)Markets are volatile right now—stocks, cryptos, you name it. But here's a crucial fact everyone is missing:...Crypto 101 Media | SponsoredYou’ve been lied to for 615 days, and countingAll of the hype around artificial intelligence has been nothing but an artificial illusion…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
